Skip to main content

Table 2 Summary of subgroup analyses

From: Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials

 

Outcome

Trial, n

SGLT2i, n

Placebo, n

Mean difference [95%CI]

Heterogeneity

(%)

Test for the overall effect

(p value)

Only Japanese patients

HbA1c (%)

13

1998

866

− 0.83 [− 1.01, − 0.65]

90

< 0.00001

TG (mg/dL)

13

2127

848

−14.39 [−20.80, −7.98]

0

< 0.0001

HDL-C (mg/dL)

12

1945

794

3.58 [2.90, 4.25]

0

< 0.00001

LDL-C (mg/dL)

12

1945

794

2.59 [0.72, 4.46]

0

0.007

LDL-C/HDL-C ratio

2

402

125

−0.04 [−0.12, 0.04]

0

0.33

Only patients treated with SGLT2i as monotherapy

HbA1c (%)

8

1596

647

−0.84 [− 0.97, − 0.70]

77

< 0.00001

TG (mg/dL)

7

1464

497

−17.96 [−27.03, −8.88]

0

0.0001

HDL-C (mg/dL)

6

1282

443

3.89 [3.01, 4.76]

0

< 0.00001

LDL-C (mg/dL)

6

1282

443

4.29 [1.81, 6.76]

0

0.0007

LDL-C/HDL-C ratio

1

307

75

−0.04 [−0.13, 0.05]

NA

0.37

  1. SGLT2i the sodium-glucose co-transporter 2 inhibitor, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, CI confidence interval, NA not applicable